Tirzepatide Pen UK: Complete Research Guide 2026

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously.

This dual mechanism distinguishes it from GLP-1-only agonists like semaglutide. By targeting two hormonal pathways, tirzepatide produces enhanced metabolic effects that have generated significant interest in the research community.

Developed originally by Eli Lilly (branded as Mounjaro for diabetes and Zepbound for weight management), tirzepatide has become one of the most studied metabolic peptides of the decade.

Tirzepatide's dual GIP/GLP-1 action produces several metabolic effects:

GLP-1 receptor activation: - Enhances glucose-dependent insulin secretion - Suppresses glucagon release - Slows gastric emptying (promotes satiety) - Acts on central appetite regulation centres

GIP receptor activation: - Promotes insulin secretion (additional to GLP-1) - Enhances fat metabolism and energy expenditure - Improves beta-cell function - Supports bone density

Combined effects: - Greater metabolic improvements than GLP-1-only compounds - More physiological appetite reduction - Improved glycaemic control - Enhanced body composition changes in clinical research

The dual mechanism is why tirzepatide has shown superior outcomes to semaglutide in head-to-head clinical trials (SURMOUNT and SURPASS programmes).

ORYN offers two distinct tirzepatide pen formats for different research needs:

ORYN Tirzepatide Pen (€169) - 10mg tirzepatide in 3mL pen - 30-day precision dosing - Multi-dose reusable pen system - >99% HPLC verified purity - Best for: Extended daily dosing research protocols

ORYN MediT Pen (€249) - 40mg tirzepatide in prefilled pen - Once-weekly single-use format - No reconstitution or dose calculation - >99% HPLC verified purity - Best for: Weekly dosing research protocols (mirrors clinical use)

Both pens are manufactured in GMP-certified ISO 7 cleanroom facilities and include a batch-specific Certificate of Analysis.

Researchers frequently compare these two metabolic peptides:

| Feature | Tirzepatide | Semaglutide | |---------|------------|-------------| | Receptor targets | GIP + GLP-1 (dual) | GLP-1 only | | Weight loss (clinical trials) | Up to 22.5% body weight | Up to 15.2% body weight | | Glycaemic control | Superior HbA1c reduction | Strong HbA1c reduction | | Approval status | Mounjaro (diabetes), Zepbound (weight) | Ozempic (diabetes), Wegovy (weight) | | Mechanism | First-in-class dual agonist | Modified GLP-1 analogue | | ORYN format | 10mg daily pen + 40mg weekly pen | Not available |

Head-to-head clinical trials (SURPASS-2) demonstrated tirzepatide's superiority to semaglutide across multiple metabolic endpoints. The dual mechanism provides additional metabolic benefits not achievable with GLP-1-only compounds.

For a detailed comparison, see our article: [Tirzepatide vs Semaglutide: Which Is Better for Research?](/learn/tirzepatide-vs-semaglutide)

Published clinical research uses the following tirzepatide dosing tiers:

- 2.5mg/week — Starting dose in clinical trials - 5mg/week — First escalation dose - 7.5mg/week — Intermediate dose - 10mg/week — Medium dose - 12.5mg/week — Higher dose - 15mg/week — Maximum studied dose in SURPASS trials

In clinical trials, doses are typically escalated every 4 weeks from 2.5mg to the target dose to minimise GI side effects.

ORYN's pens allow flexible dosing: - The 10mg Tirzepatide Pen (3mL, 30 doses) delivers ~333mcg per daily dose, or can be adjusted for less frequent administration. - The 40mg MediT Pen delivers a single weekly dose, aligning with the clinical trial format.

Important: All dosing information is from published clinical literature. ORYN products are for research use only.